A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Clinical trial NCT03906526 · TERMINATED

Trial details

NCT number: NCT03906526
Sponsor: Celgene
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Squamous Cell

Start date: 2019-07-03
Primary completion: 2022-01-24
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.